In this review:
Safety and efficacy of intrathecalMSC-NTF in progressive MS
Effects of evobrutinib on slowly expanding lesions in RMS
Ublituximab vs teriflunomide in RMS: the ULTIMATE studies
Long-term efficacy of ocrelizumab in RMS: the OPERA OLE
Early treatment efficacy with alemtuzumab is maintained over 10 years
Significance of MOG antibodies in CSF
Barcelona baseline risk score predicts long-term prognosis
Allogeneic Epstein-Barr virustargeted T-cell immunotherapy for progressive MS
Cortical lesions at diagnosis predict conversion to SPMS
Long COVID among people with MS
Please login below to download this issue (PDF)